Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

Trial Profile

Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Anterior uveitis; Corneal disorders; Ocular inflammation; Pemphigoid
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 05 Oct 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017, as reported by ClinicalTrials.gov.
    • 05 Oct 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top